Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study
- Population
- Patients with acute myelocytic leukemia, reported in two age groups: younger than 60 years and older than 60 years.
- Design
- Randomised comparison, as described in the abstract, of daunorubicin 30 mg/m2, daunorubicin 45 mg/m2 or adriamycin 30 mg/m2 given on days 1 to 3 of a 7-day continuous infusion of cytosine arabinoside 100 mg/m2 per day; patients in remission received cyclic maintenance courses every 4 or every 8 weeks. The abstract names no control arm: the arm roles recorded here are a schema requirement.
- Arms
- Daunorubicin 30 mg/m2 (control): Daunorubicin 30 mg/m2 on days 1 to 3 plus cytarabine 100 mg/m2 per day by continuous infusion for 7 days
- Daunorubicin 45 mg/m2 (experimental): Daunorubicin 45 mg/m2 on days 1 to 3 plus cytarabine 100 mg/m2 per day by continuous infusion for 7 days
- Adriamycin 30 mg/m2 (experimental): Adriamycin (doxorubicin) 30 mg/m2 on days 1 to 3 plus cytarabine 100 mg/m2 per day by continuous infusion for 7 days
- People
- Yates J, Cancer and Leukemia Group B
Δ Complete remission rate+13 pointsΔ Complete remission rate−16 points
Show the numbers
| Endpoint | Analysis | Daunorubicin 45 mg/m2 / Adriamycin 30 mg/m2 | Daunorubicin 30 mg/m2 | Effect |
|---|---|---|---|---|
| Complete remission ratePatients younger than 60 years | primaryYates 1982 | 72% | 59% | The abstract states that daunorubicin 45 was significantly better than the other two arms in this age group; it gives no P value, confidence interval or number of patients per arm. |
| Complete remission ratePatients older than 60 years | primaryYates 1982 | 31% | 47% | The abstract states that daunorubicin 30 was better than the other two arms in this age group, with a corresponding shift in induction mortality (no figures given); it gives no P value, confidence interval or number of patients per arm. |
| Endpoint | Analysis | Daunorubicin 45 mg/m2 / Adriamycin 30 mg/m2 | Daunorubicin 30 mg/m2 | Effect |
|---|---|---|---|---|
| Complete remission ratePatients younger than 60 years | primaryYates 1982 | 72% | 59% | The abstract states that daunorubicin 45 was significantly better than the other two arms in this age group; it gives no P value, confidence interval or number of patients per arm. |
| Complete remission ratePatients older than 60 years | primaryYates 1982 | 31% | 47% | The abstract states that daunorubicin 30 was better than the other two arms in this age group, with a corresponding shift in induction mortality (no figures given); it gives no P value, confidence interval or number of patients per arm. |
Appears in
Sources
Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982;60(2):454-62.